Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Antimicrobial resistance of staphylococci and streptococci isolated from dogs.

Tropical biomedicine·2021

Same author

The Management of Relapsed and Refractory Acute Myeloid Leukaemia in Adults.

Leukemia & lymphoma·2016

Same author

Systemic Irradiation Therapy of Myelomatosis-The Therapeutic Implications of Technique.

Leukemia & lymphoma·2016

Same author

A Pilot Study Using Intravenous Immunoglobulin for the Prevention of Infection During Remission Induction in Acute Leukaemia.

Leukemia & lymphoma·2016

Same author

Editorial.

Hematology (Amsterdam, Netherlands)·2016

Same author

Non-inpatient Treatment of Febrile Episodes in Patients with Hematological Malignancy.

Hematology (Amsterdam, Netherlands)·2016

Same journal

Raloxifene inhibits the proliferation of pediatric acute myeloid leukemia by targeting the ANP32B gene and regulating C-MYC expression.

Hematology (Amsterdam, Netherlands)·2026

Same journal

Characterization of a novel α-thalassemia deletion (Dongxing deletion; --<sup>DX</sup>) by CNV-seq in a Chinese female with Hb H disease: a case report.

Hematology (Amsterdam, Netherlands)·2026

Same journal

Real-world pegcetacoplan treatment of paroxysmal nocturnal hemoglobinuria patients with an unsatisfactory response to prior therapies.

Hematology (Amsterdam, Netherlands)·2026

Same journal

Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single-center retrospective study.

Hematology (Amsterdam, Netherlands)·2026

Same journal

Sirolimus-based treatment regimens for antinuclear antibody (ANA)-positive immune thrombocytopenia: a retrospective single-center cohort study.

Hematology (Amsterdam, Netherlands)·2026

Same journal

Relationship between major depressive disorder and venous thromboembolism: a five-ancestry genetic analysis.

Hematology (Amsterdam, Netherlands)·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 17, 2026

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

Interleukin-3: Promises and Perspectives.

M H Mangi¹, A C Newland¹

¹a Department of Haematology , The Royal London Hospital , London E1 1BB.

Hematology (Amsterdam, Netherlands)

|July 15, 2016

Summary

This summary is machine-generated.

Interleukin-3 (IL-3) shows potential in enhancing hematopoietic stem cell regeneration and peripheral blood stem cell harvesting, especially when combined with other cytokines. While initial results in cancer treatment were mixed, IL-3 holds promise for future combination therapies.

Keywords:

Interleukin-3 (IL-3)cytokines dose intensification growth factors hematopoiesis immune modulation interleukins peripheral blood stem cells (PBSC)

More Related Videos

An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses

An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses

Published on: July 7, 2017

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

Related Experiment Videos

Last Updated: Mar 17, 2026

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses

An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses

Published on: July 7, 2017

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

Area of Science:

Hematology
Immunology
Oncology

Background:

Interleukin-3 (IL-3) is a multipotent hematopoietic growth factor.
Its receptor comprises alpha and beta subunits, sharing the beta subunit with GM-CSF and IL-5.
IL-3 influences proliferation, maturation, and self-renewal of hematopoietic stem cells and myeloid lineages.

Purpose of the Study:

To evaluate the therapeutic potential of recombinant human IL-3 (rhIL-3) in various clinical settings.
To assess IL-3's efficacy in treating myelodysplastic syndromes (MDS) and aplastic anemia (AA).
To explore IL-3's role in peripheral blood stem cell (PBSC) harvesting and ex-vivo stem cell expansion.

Main Methods:

Clinical trials (Phase I/II and III) involving rhIL-3 administration.
In vitro studies using hematopoietic cell lines and bone marrow cells.
Combination therapy studies with chemotherapy, immunosuppression, and other cytokines (GM-CSF, G-CSF).

Main Results:

Phase I/II trials showed IL-3 reduced chemotherapy delays and accelerated granulocyte/platelet regeneration, but Phase III results were inconclusive.
IL-3 monotherapy for MDS and AA was disappointing, but combination therapies showed encouraging results.
IL-3 combined with other growth factors increased PBSC yields during harvesting.

Conclusions:

IL-3's therapeutic role in oncology and non-oncology patients is still being defined.
Combination therapy with IL-3 and other cytokines appears promising for preventing treatment-related mortality in cancer patients.
Further research is needed for IL-3's application in ex-vivo stem cell expansion, dendritic cell development, and gene transfer.